TSE:EVGN Evogene (EVGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Evogene Stock (TSE:EVGN) 30 days 90 days 365 days Advanced Chart Get Evogene alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetC$3.00Consensus RatingBuy Company OverviewEvogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., seed traits through the Ag-Seeds division, and ag-solutions for castor oil production through Casterra Ltd.Read More… Receive EVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. Email Address EVGN Stock News HeadlinesICL acquires Evogene subsidiary Lavie BioApril 22, 2025 | uk.investing.comEvogene-Aktie erreicht 52-Wochen-Tief bei 0,99 US-DollarApril 15, 2025 | de.investing.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.May 14, 2025 | Crypto Swap Profits (Ad)Evogene-Aktie erreicht 52-Wochen-Tief bei 1,18 US-DollarApril 5, 2025 | de.investing.comEvogene price target lowered to $6 from $11.25 at Alliance Global PartnersMarch 7, 2025 | markets.businessinsider.comEvogene Ltd (EVGN) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...March 7, 2025 | gurufocus.comQ4 2024 Evogene Ltd Earnings Call TranscriptMarch 7, 2025 | gurufocus.comEvogene verfehlt Umsatzerwartungen im vierten Quartal, Aktien geben nachMarch 6, 2025 | de.investing.comSee More Headlines EVGN Stock Analysis - Frequently Asked Questions How do I buy shares of Evogene? Shares of EVGN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Evogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include Acacia Communications (ACIA), Hyliion (HYLN), Purple Biotech (PPBT), Viper Networks (VPER), Butterfly Network (BFLY), Alibaba Group (BABA) and AquaBounty Technologies (AQB). Industry, Sector and Symbol Stock ExchangeTSE SectorManufacturing Industry Pesticide & Other Agricultural Chemical Manufacturing Sub-IndustryChemicals Current SymbolTSE:EVGN CIKN/A Webwww.evogene.com Phone97289311900FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price TargetC$3.00 High Stock Price TargetC$3.00 Low Stock Price TargetC$3.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (TSE:EVGN) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s third-term comments grabbed headlines, but the bigger story is what he’s planning next. A new report ...Porter & Company | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredA New Economic Shift – How You Can PrepareWhile everyone's focused on the Fed and interest rates... most investors are missing the real story. There'...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredDrop these 5 stocks now!You think the volatility is over? Think again … Because it’s just getting started. In fact, according...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.